These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 24791508)
21. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885 [TBL] [Abstract][Full Text] [Related]
22. The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. Kim JE; Cho HJ; Kim JS; Shim CK; Chung SJ; Oak MH; Yoon IS; Kim DD Xenobiotica; 2013 Jul; 43(7):579-91. PubMed ID: 23252722 [TBL] [Abstract][Full Text] [Related]
23. Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure. White MP; Babayeva M; Taft DR; Maniar M J Pharm Pharmacol; 2013 Jul; 65(7):960-9. PubMed ID: 23738723 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography-mass spectrometry method: a study on bioavailability and dose proportionality. Sun J; Zhang L; Song J; Tian S; Huang C; Feng Z; Lv Y; Du G J Ethnopharmacol; 2013 Jul; 148(2):617-23. PubMed ID: 23707334 [TBL] [Abstract][Full Text] [Related]
25. Investigation of Molecular Properties that Influence the Permeability and Oral Bioavailability of Major β-Boswellic Acids. Sharma T; Jana S Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):243-255. PubMed ID: 31786725 [TBL] [Abstract][Full Text] [Related]
26. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Kamath AV; Chong S; Chang M; Marathe PH Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193 [TBL] [Abstract][Full Text] [Related]
27. Absorption and metabolism of caffeic acid and chlorogenic acid in the small intestine of rats. Lafay S; Morand C; Manach C; Besson C; Scalbert A Br J Nutr; 2006 Jul; 96(1):39-46. PubMed ID: 16869989 [TBL] [Abstract][Full Text] [Related]
28. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models. Sun H; Bi H; Huang M; Liu D; Qin Z Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649 [TBL] [Abstract][Full Text] [Related]
29. Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats. Sun J; Song J; Zhang W; Jing F; Xu W; Leng P; Quan X; Du G; Sui Z Pharm Biol; 2018 Dec; 56(1):399-406. PubMed ID: 30122142 [TBL] [Abstract][Full Text] [Related]
30. A nanostructured liquid crystalline formulation of 20(S)-protopanaxadiol with improved oral absorption. Jin X; Zhang ZH; Li SL; Sun E; Tan XB; Song J; Jia XB Fitoterapia; 2013 Jan; 84():64-71. PubMed ID: 23006538 [TBL] [Abstract][Full Text] [Related]
31. [Oral bioavailability and intestinal disposition of dehydroandrographolide in rats]. Ye L; Liang F; Yang X; Shi J; Wang F; Liu W; Zhao J; Liu Z Nan Fang Yi Ke Da Xue Xue Bao; 2012 Aug; 32(8):1074-81. PubMed ID: 22931595 [TBL] [Abstract][Full Text] [Related]
32. Improvement of intestinal absorption of forsythoside A in weeping forsythia extract by various absorption enhancers based on tight junctions. Zhou W; Qin KM; Shan JJ; Ju WZ; Liu SJ; Cai BC; Di LQ Phytomedicine; 2012 Dec; 20(1):47-58. PubMed ID: 23089157 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Hao H; Wang G; Cui N; Li J; Xie L; Ding Z Planta Med; 2006 Nov; 72(14):1311-7. PubMed ID: 17024606 [TBL] [Abstract][Full Text] [Related]
34. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. Sharma P; Varma MV; Chawla HP; Panchagnula R Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320 [TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Kamath AV; Wang J; Lee FY; Marathe PH Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625 [TBL] [Abstract][Full Text] [Related]
36. The absorption of oral morroniside in rats: In vivo, in situ and in vitro studies. Xiong S; Li J; Mu Y; Zhang Z Acta Pharm; 2019 Jun; 69(2):287-296. PubMed ID: 31259727 [TBL] [Abstract][Full Text] [Related]
37. Investigating permeability related hurdles in oral delivery of 11-keto-β-boswellic acid. Bagul P; Khomane KS; Bansal AK Int J Pharm; 2014 Apr; 464(1-2):104-10. PubMed ID: 24463070 [TBL] [Abstract][Full Text] [Related]
38. Microbial metabolites of ingested caffeic acid are absorbed by the monocarboxylic acid transporter (MCT) in intestinal Caco-2 cell monolayers. Konishi Y; Kobayashi S J Agric Food Chem; 2004 Oct; 52(21):6418-24. PubMed ID: 15479001 [TBL] [Abstract][Full Text] [Related]
39. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Sun Y; Sun J; Shi S; Jing Y; Yin S; Chen Y; Li G; Xu Y; He Z Mol Pharm; 2009; 6(1):315-25. PubMed ID: 19115956 [TBL] [Abstract][Full Text] [Related]
40. Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption. Chougule MB; Patel AR; Patlolla R; Jackson T; Singh M J Drug Target; 2014 Jul; 22(6):498-508. PubMed ID: 24731057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]